ArticleBMC cancer2025
Association between antihypertensive drugs and cancer risk: evidence from a population-based study in the Abruzzo region, Southern Italy.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, the relationship between the use of antihypertensive medications and the risk of developing cancer has been examined yielding heterogeneous results. Using routinely administrative regional healthcare databases from the Abruzzo Region (in Southern Italy), a retrospective cohort study between the years 2017–2024 was conducted investigating the relationship between the use of antihypertensive drugs and the risk of cancer occurrence, by a descriptive-population based approach.
methodsAll Regional Health Service beneficiaries without a cancer diagnosis in the two preceding years, incident users of at least one antihypertensive drug (ACEIs, ARBs, CCBs, BBs or Loop/Thiazides diuretics) were identified. Participants were followed from the “index date” until September 2024 and classified based on the initial antihypertensive drug prescribed. Associations between antihypertensive drugs and cancer risk were evaluated using multivariable Cox proportional hazards. A sensitivity analysis was also conducted for certain tumour Macroclasses, defined in accordance with ICD-9-CM classification.
resultsFive hundred twenty-six thousand, three hundred ninety-four individuals were identified as users of at least one antihypertensive drug. Of these, 87 987 individuals met the inclusion criteria and comprised the final cohort (median age 60 years, IQR: 51–69; 48.3% males). Over a median follow-up of 47.8 months (IQR: 21.0–72.0), 3 577 individuals (4.1%) received a cancer diagnosis and the overall number of cancer cases was 3.6% for ACEIs, 3.5% for ARBs, 3.8% for BBs, 3.6% for CCBs, 3.5% for Thiazides and 5.4% for Loop. Our models show a reduced risk of cancer occurrence among users of ACEIs, ARBs, BBs, CCBs, and thiazides (HR: 0.88; 0.83; 0.90; 0.86; 0.85; respectively), whereas treatment with Loop diuretics was associated with a significantly modest risk increase (HR: 1.47), particularly for the malignant neoplasm of digestive organs and peritoneum; respiratory and intrathoracic organs; bone, connective tissue, skin and breast; other and unspecified sites; lymphatic and hematopoietic tissue tumour Macroclasses; as well as in patients in the same tumour Macroclasses but treated with ACEIs.
conclusionOur observational study from the general population of the Abruzzo analysed the association between antihypertensive treatment and cancer risk providing comforting evidence about the oncological safety for many antihypertensive drug classes, apart from Loop diuretics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.